ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Fountain Displays Some Statesmanship

July 8, 1977

NCI Official Says Public Health Issue As Important As Data In Mammography

April 2, 1993

In Brief: ACS Awards Professorship To Bernstein; HCFA Clears Dana-Farber For Medicare

August 11, 1995

Southwest, Children’s Cooperative Groups Get Cancer To Extend Research Into Community Hospitals

October 8, 1976

RFP Suggestions For Immunodiagnosis Research Offered

October 22, 1976

FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer

September 27, 2013